Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CTSG | P08311 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10180071 | 0.82 | SLC6A2 (0.49) | GABRA1GABRB2ELANEATMCTSG | |
| SCHEMBL4657831 | 0.81 | GABRA1 (0.48) | GABRA1GABRB2ELANEATMCTSG | |
| SCHEMBL10180745 | 0.81 | GABRA1 (0.44) | GABRA1GABRB2ELANEATMCTSG | |
| SCHEMBL674104 | 0.81 | CA2 (0.45) | GABRA1GABRB2ATMCA2GAA | |
| SCHEMBL10181745 | 0.80 | GABRA1 (0.40) | GABRA1GABRB2ELANEATMCTSG | |
| SCHEMBL10181391 | 0.80 | GABRA1 (0.40) | GABRA1GABRB2ELANEATMCTSG | |
| SCHEMBL11658387 | 0.79 | GABRA1 (0.42) | GABRA1GABRB2ELANEATMCTSG | |
| Potassium Ion SCHEMBL23749101 | 0.79 | GABRA1 (0.42) | GABRA1GABRB2ELANEATMCTSG | |
| Ammonia Solution, Strong SCHEMBL23749128 | 0.79 | GABRA1 (0.47) | GABRA1GABRB2ELANEATMCTSG | |
| Hydrochloric Acid SCHEMBL14638222 | 0.79 | CA2 (0.45) | GABRA1GABRB2ELANEATMCTSG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| WO-2023014979-A9 | CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR KRAS G12C PROTEINS | RAYZEBIO, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023282702-A1 | SHP2 INHIBITOR AND USE THEREOF | 주식회사 카나프테라퓨틱스 | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029739-B2 | SHP2 inhibitor and use thereof | PTPN1, PTPN5, PTPN2 | GABRA1 3503/4885GABRB2 3659/4885ELANE 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.